middle.news
EMVision Clears 230 Patient Trial Mark as FDA Strategy Expands
8:53am on Monday 26th of October, 2026 AEDT
•
Medical Technology
Read Story
EMVision Clears 230 Patient Trial Mark as FDA Strategy Expands
8:53am on Monday 26th of October, 2026 AEDT
Key Points
Pivotal emu™ trial exceeds 230 participants toward a 300-patient primary cohort
Acute ischaemic stroke detection feature to be discussed with the FDA
First Responder mobile stroke unit study completes Stage 1 usability objectives
Production-equivalent First Responder units targeted for H1 CY27
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Emvision Medical Devices (ASX:EMV)
OPEN ARTICLE